A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients.

Autor: de Jonge AV; Department of Hematology, Amsterdam UMC location VU, Amsterdam, The Netherlands. a.dejonge1@amsterdamumc.nl., van Werkhoven E; HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Dinmohamed AG; Department of Hematology, Amsterdam UMC location VU, Amsterdam, The Netherlands.; Erasmus MC, Department of Public Health, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands., Nijland M; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands., Zwinderman AH; Department of Clinical Epidemiology, Biostatistics, and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Bossuyt PM; Department of Clinical Epidemiology, Biostatistics, and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Veldhuis MS; Department of Hematology, Amsterdam UMC location VU, Amsterdam, The Netherlands., Rutten EGGM; Department of Pathology, Amsterdam UMC location VU, Amsterdam, The Netherlands., Mous R; Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands., Vermaat JSP; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Sandberg Y; Department of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands., de Jongh E; Department of Hematology, Albert Schweitzer Ziekenhuis, Dordrecht, The Netherlands., Bilgin YM; Department of Internal Medicine, Adrz, Goes, The Netherlands., Boersma R; Department of Internal Medicine, Amphia Ziekenhuis, Breda, The Netherlands., Koene H; Department of Hematology, St Antonius Ziekenhuis, Nieuwegein, The Netherlands., Kersten MJ; Department of Hematology, Amsterdam UMC location VU, Amsterdam, The Netherlands., de Jong D; Department of Pathology, Amsterdam UMC location VU, Amsterdam, The Netherlands., Chamuleau MED; Department of Hematology, Amsterdam UMC location VU, Amsterdam, The Netherlands.
Jazyk: angličtina
Zdroj: Blood cancer journal [Blood Cancer J] 2023 May 22; Vol. 13 (1), pp. 85. Date of Electronic Publication: 2023 May 22.
DOI: 10.1038/s41408-023-00854-2
Abstrakt: Patients with MYC rearranged (MYC-R) diffuse large B-cell lymphoma (DLBCL) have a poor prognosis. Previously, we demonstrated in a single-arm phase II trial (HOVON-130) that addition of lenalidomide to R-CHOP (R2CHOP) is well-tolerated and yields similar complete metabolic remission rates as more intensive chemotherapy regimens in literature. In parallel with this single-arm interventional trial, a prospective observational screening cohort (HOVON-900) was open in which we identified all newly diagnosed MYC-R DLBCL patients in the Netherlands. Eligible patients from the observational cohort that were not included in the interventional trial served as control group in the present risk-adjusted comparison. R2CHOP treated patients from the interventional trial (n = 77) were younger than patients in the R-CHOP control cohort (n = 56) (median age 63 versus 70 years, p = 0.018) and they were more likely to have a lower WHO performance score (p = 0.013). We adjusted for differences at baseline using 1:1 matching, multivariable analysis, and weighting using the propensity score to reduce treatment-selection bias. These analyses consistently showed improved outcome after R2CHOP with HRs of 0.53, 0.51, and 0.59, respectively, for OS, and 0.53, 0.59, and 0.60 for PFS. Thus, this non-randomized risk-adjusted comparison supports R2CHOP as an additional treatment option for MYC-R DLBCL patients.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: